Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics Inc. (SRPT)
:SRPT
SRPT Stock Chart & Stats
$21.14
$1.44(1.16%)
At close: 4:00 PM EST
$21.14
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $129.84
Previous CloseN/A
Volume185.86K
Average Volume (3M)3.93M
Market Cap
$2.34B
Enterprise Value$2.33B
Total Cash (Recent Filing)$850.99M
Total Debt (Recent Filing)$1.25B
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 03, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding104,787,186
10 Day Avg. Volume3,232,409
30 Day Avg. Volume3,931,832
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.57
Price to Sales (P/S)6.08
P/FCF Ratio-33.73
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda-11.98
Forecast
1Y Price Target
$21.24Price Target Upside0.47% Upside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-4.99
Revenue Forecast (FY)$2.12B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal product revenue for the quarter was $399.4 million, beating both analyst estimates and consensus.
Product SalesExon-skipping products have stably generated close to $1B in annual sales, and there is projected continued patient uptake based on a high compliance rate reported by SRPT.
Regulatory ApprovalThe FDA approval to initiate ENDEAVOR Cohort 8 is seen as a constructive step toward addressing safety concerns that have limited Elevidys access for non-ambulatory patients.
Bears Say
Market CompetitionHalf of the total addressable market may be depleted, with hundreds of valuable patients diverted to an FDA-mandated post-marketing study and competitor DMD trials adding pressure.
Regulatory RisksThe FDA's latest label action elevates Elevidys into a heightened-surveillance category, materially weakening the commercial narrative.
Trial FailureThe recent failure of the ESSENCE trial could put Vyondys 53 and Amondys 45 at risk of losing marketing authorization.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Sarepta Therapeutics Inc. lowest stock price was $10.41 and its highest was $129.84 in the past 12 months.
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is $2.34B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 74 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on Nov 03, 2025. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$1.073.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is -1.34.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Sarepta Therapeutics Inc. has 104,787,186 shares outstanding.
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of -$1.8 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -33.742%.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.24 (0.47% Upside)
$21.24 (0.47% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 638.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.19%
12-Months-Change
Fundamentals
Return on Equity
-21.37%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics (SRPT) is a biotechnology company focused on developing innovative genetic medicine therapies to treat rare diseases, particularly those related to muscular dystrophies. The company specializes in the development of RNA-targeted therapies, including exon-skipping technologies, to address the underlying causes of these genetic disorders. Its core products include the FDA-approved drug Eteplirsen, aimed at treating Duchenne muscular dystrophy (DMD), along with a robust pipeline of therapies in various stages of clinical development.
SRPT Company Deck
SRPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in revenue and study completions, alongside challenges such as the ESSENCE trial missing statistical significance and disruptions from paused shipments.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$21.24
▲(0.47% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
5.25% Insiders
14.56% Mutual Funds
17.30% Other Institutional Investors
37.83% Public Companies and Individual Investors